 | • レポートコード：MRC2307A0149 • 出版社/出版日：Transparency Market Research / 2023年4月 • レポート形態：英文、PDF、201ページ • 納品方法：Eメール • 産業分類：化学＆材料 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本報告書は、世界の小細胞肺がん（SCLC）治療薬市場規模が、2023年の46億ドルから予測期間中、年平均11.9％で成長し、2031年には129億ドルに達すると予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療タイプ別（標的療法、免疫療法、化学療法）分析、薬剤種類別（アテゾリズマブ、デュルバルマブ、ルルビネクテディン、ペンブロリズマブ、その他）分析、投与経路別（経口、非経口、その他）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの構成でまとめています。なお、当市場の主要企業には、AstraZeneca plc、Dr. Reddy's Laboratories, Inc.、F. Hoffmann La-Roche Ltd.、GSK plc、Jazz Pharmaceuticals plc、Merck & Co., Inc.、Novartis AG、Pfizer Inc.などがあります。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の小細胞肺がん（SCLC）治療薬市場規模：治療タイプ別 - 標的療法の市場規模 - 免疫療法の市場規模 - 化学療法の市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：薬剤種類別 - アテゾリズマブの市場規模 - デュルバルマブの市場規模 - ルルビネクテディンの市場規模 - ペンブロリズマブの市場規模 - その他の市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：投与経路別 - 経口剤の市場規模 - 非経口剤の市場規模 - その他投与経路の市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：流通チャンネル別 - 病院薬局チャンネルの市場規模 - 小売薬局チャンネルの市場規模 - オンライン薬局チャンネルの市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：地域別 - 北米の小細胞肺がん（SCLC）治療薬市場規模 - ヨーロッパの小細胞肺がん（SCLC）治療薬市場規模 - アジア太平洋の小細胞肺がん（SCLC）治療薬市場規模 - 中南米の小細胞肺がん（SCLC）治療薬市場規模 - 中東・アフリカの小細胞肺がん（SCLC）治療薬市場規模 ・競争状況 |
Small Cell Lung Cancer (SCLC) Therapeutics Market – Scope of Report
TMR’s report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Small Cell Lung Cancer (SCLC) Therapeutics Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Small Cell Lung Cancer (SCLC) Therapeutics Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.
The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Small Cell Lung Cancer (SCLC) Therapeutics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Small Cell Lung Cancer (SCLC) Therapeutics Market profiled in this report.
Key Questions Answered in Global Small Cell Lung Cancer (SCLC) Therapeutics Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Small Cell Lung Cancer (SCLC) Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Small Cell Lung Cancer (SCLC) Therapeutics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Therapy Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017 – 2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key Industry Events
5.4. COVID-19 Impact on Industry
6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2017 – 2031
6.3.1. Targeted Therapy
6.3.2. Immunotherapy
6.3.3. Chemotherapy
6.4. Market Attractiveness, by Therapy Type
7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Drug Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Type, 2017 – 2031
7.3.1. Atezolizumab
7.3.2. Durvalumab
7.3.3. Lurbinectedin
7.3.4. Pembrolizumab
7.3.5. Etoposide
7.3.6. Methotrexate
7.3.7. Topotecan
7.3.8. Others
7.4. Market Attractiveness, by Drug Type
8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017 – 2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness, by Route of Administration
9. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017 – 2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017 – 2031
11.2.1. Targeted Therapy
11.2.2. Immunotherapy
11.2.3. Chemotherapy
11.3. Market Value Forecast, by Drug Type, 2017 – 2031
11.3.1. Atezolizumab
11.3.2. Durvalumab
11.3.3. Lurbinectedin
11.3.4. Pembrolizumab
11.3.5. Etoposide
11.3.6. Methotrexate
11.3.7. Topotecan
11.3.8. Others
11.4. Market Value Forecast, by Route of Administration, 2017 – 2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017 – 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Therapy Type
11.7.2. By Drug Type
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017 – 2031
12.2.1. Targeted Therapy
12.2.2. Immunotherapy
12.2.3. Chemotherapy
12.3. Market Value Forecast, by Drug Type, 2017 – 2031
12.3.1. Atezolizumab
12.3.2. Durvalumab
12.3.3. Lurbinectedin
12.3.4. Pembrolizumab
12.3.5. Etoposide
12.3.6. Methotrexate
12.3.7. Topotecan
12.3.8. Others
12.4. Market Value Forecast, by Route of Administration, 2017 – 2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country, 2017 – 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Therapy Type
12.7.2. By Drug Type
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country
13. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017 – 2031
13.2.1. Targeted Therapy
13.2.2. Immunotherapy
13.2.3. Chemotherapy
13.3. Market Value Forecast, by Drug Type, 2017 – 2031
13.3.1. Atezolizumab
13.3.2. Durvalumab
13.3.3. Lurbinectedin
13.3.4. Pembrolizumab
13.3.5. Etoposide
13.3.6. Methotrexate
13.3.7. Topotecan
13.3.8. Others
13.4. Market Value Forecast, by Route of Administration, 2017 – 2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country, 2017 – 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Therapy Type
13.7.2. By Drug Type
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country
14. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017 – 2031
14.2.1. Targeted Therapy
14.2.2. Immunotherapy
14.2.3. Chemotherapy
14.3. Market Value Forecast, by Drug Type, 2017 – 2031
14.3.1. Atezolizumab
14.3.2. Durvalumab
14.3.3. Lurbinectedin
14.3.4. Pembrolizumab
14.3.5. Etoposide
14.3.6. Methotrexate
14.3.7. Topotecan
14.3.8. Others
14.4. Market Value Forecast, by Route of Administration, 2017 – 2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Therapy Type
14.7.2. By Drug Type
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country
15. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapy Type, 2017 – 2031
15.2.1. Targeted Therapy
15.2.2. Immunotherapy
15.2.3. Chemotherapy
15.3. Market Value Forecast, by Drug Type, 2017 – 2031
15.3.1. Atezolizumab
15.3.2. Durvalumab
15.3.3. Lurbinectedin
15.3.4. Pembrolizumab
15.3.5. Etoposide
15.3.6. Methotrexate
15.3.7. Topotecan
15.3.8. Others
15.4. Market Value Forecast, by Route of Administration, 2017 – 2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by Distribution Channel, 2017 – 2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country, 2017 – 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Therapy Type
15.7.2. By Drug Type
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. AstraZeneca plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Test Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Dr. Reddy’s Laboratories, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Test Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann La-Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Test Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. GSK plc
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Test Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Jazz Pharmaceuticals plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Test Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co., Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Test Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Test Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Pfizer Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Test Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 08: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 09: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 10: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 12: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 13: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 14: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 15: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 18: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 19: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 22: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 23: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 24: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 25: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 27: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
Table 28: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 29: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 30: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031